The Advanced Research Projects Agency for Health (ARPA-H) has launched its most ambitious genomics initiative to date, awarding up to $160 million to seven research teams under a new program called THRIVE. The goal: develop scalable platforms for creating custom, individualized gene editing therapies — so-called “n-of-1” treatments — for patients with rare genetic diseases.
The Scale Problem in Gene Therapy
Gene editing technologies like CRISPR-Cas9 and base editing have demonstrated remarkable therapeutic potential, but they face a fundamental scalability challenge. Each rare genetic disease — and in many cases, each individual patient’s mutation — requires a unique therapeutic construct. Designing, testing, manufacturing, and gaining regulatory approval for thousands of individualized treatments using traditional approaches would take decades and cost billions.
THRIVE aims to compress this timeline dramatically by funding the development of AI-driven platforms that can automate the design of custom base-editing therapies. The seven selected research teams will work on building computational pipelines that can rapidly identify target mutations, design appropriate guide sequences, predict off-target effects, and optimize delivery vectors — all at a pace and scale that manual approaches cannot match.
AI as the Enabling Layer
The THRIVE program sits squarely at the intersection of artificial intelligence and precision medicine. Designing a custom gene edit for an individual patient requires analyzing genomic data, predicting protein structure impacts, modeling cellular behavior, and optimizing therapeutic delivery — tasks that are increasingly within the capabilities of modern AI systems trained on biological data.
This is where recent advances in protein structure prediction, genomic foundation models, and computational biology converge with clinical need. The platforms funded under THRIVE will need to integrate these capabilities into end-to-end workflows that can produce clinically viable therapies, not just theoretical designs.
The Largest Federal Bet on Personalized Gene Therapy
At $160 million, THRIVE represents the U.S. government’s largest single investment in personalized gene therapy infrastructure. The program reflects a growing recognition that rare diseases — which collectively affect an estimated 30 million Americans across more than 7,000 conditions — cannot be addressed by traditional drug development economics.
For the broader healthcare AI community, THRIVE signals that federal research agencies view AI not as an incremental efficiency tool but as a foundational capability for making previously impossible therapeutic approaches viable. If successful, the platforms developed under this program could establish a blueprint for AI-enabled personalized medicine that extends well beyond rare diseases.
The program joins a growing portfolio of ARPA-H initiatives aimed at transforming healthcare through technology. With its emphasis on scalability, computational design, and clinical translation, THRIVE may prove to be one of the most consequential federal health research investments of the decade.
